Citadel Advisors
CANF

Citadel Advisors’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Citadel Advisors’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7
Closed -$25K – 9225
2018
Q2 		$25K Buy
+7
New +$27.9K ﹤0.01% 8595

Other funds holding CANF

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Citadel Advisors's CANF Position: Q1 2026 in Review

Citadel Advisors opened a new position in Can-Fite BioPharma American Depositary Shares (CANF) in Q1 2026: 34,150 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #11970 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CANF as recently as Q1 2024.

Citadel Advisors first reported a position in CANF in Q1 2015 and has held it in 12 quarters since. The position peaked at $148K in Q1 2021. 14 funds tracked by Wall St. Rank hold CANF as of Q1 2026.

  • Citadel Advisors held 34,150 shares of Can-Fite BioPharma American Depositary Shares worth $106K as of Q1 2026.
  • Can-Fite BioPharma American Depositary Shares was a new Citadel Advisors position in Q1 2026.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11970 holding.
  • Citadel Advisors first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2015 and has held it in 12 quarters since.
  • Citadel Advisors's Can-Fite BioPharma American Depositary Shares position peaked at $148K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.